Because cancers with WT p53 often have other mechanisms that suppress or inactivate the p53 response, primarily loss of p19ARF and MDM2 amplification, inhibiting the p53-MDM2 interaction can be a beneficial strategy. The gene discussed is MDM2; the disease is cancer.